About eXmoor
eXmoor is a company based in Bristol (United Kingdom) founded in 2004. eXmoor has raised $51.75 million across 2 funding rounds from investors including MVM Partners and Kineticos. eXmoor offers products and services including Process Development, GMP Manufacture, Fill and Finish, and QP Release. eXmoor operates in a competitive market with competitors including Orgenesis, Ori Biotech, MaSTherCell, Cognate Bioservices and Cell-Easy, among others.
- Headquarter Bristol, United Kingdom
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website exmoorpharma.com
- Social LinkedIn X
- Legal Name Exmoor Pharma Concepts Limited
- Date of Incorporation 03 Mar, 2004
- Jurisdiction TAUNTON, SOMERSET, UNITED KINGDOM
- Total Equity Funding$51.75M (USD)
in 2 rounds
- Latest Funding Round$35M (USD), Series A
May 2023
- InvestorsMVM Partners
& 1 more
Products & Services of eXmoor
eXmoor offers a comprehensive portfolio of products and services, including Process Development, GMP Manufacture, Fill and Finish, and QP Release.
Early stage support for therapy development and scale-up
Production of viral vectors and cell therapies
Final packaging and quality release of therapies
Certification for regulatory compliance in therapies
Funding Insights of eXmoor
eXmoor has successfully raised a total of $51.75M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $35 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $51.75M
- Total Rounds 2
- Last Round Series A — $35M
- First Round $16.75M
(Mar 2021)
- Investors Count 2
All 2 funding rounds of eXmoor with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in eXmoor
eXmoor has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include MVM Partners and Kineticos.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments in healthcare companies are managed. | 1997 | mvm.com | London, United Kingdom | |
Invests in early-stage life sciences companies for innovation, expertise, and growth. | 2012 | kineticos.com | Morrisville, United States |
Investor details for eXmoor
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of eXmoor
37 people are tracked at eXmoor (8 in leadership, 29 in team).
| Name | Role | Group |
|---|---|---|
Emma Ewins | Head Of GMP | Leadership |
Lucy Foley | CTO | Leadership |
Angela Osborne | CEO | Leadership |
Graham Henderson | Chief Financial Officer | Leadership |
Ian Rhodes | Director, Finance & Consultancy | Leadership |
Termeh Raji | Head of Operations | Leadership |
Gavin Sutton | Operations Director | Leadership |
David Vincent | Head of Process Development | Leadership |
Sheabul Hoque | GMP QC Team Lead | Team |
Tara Lewin | Procurement Assistant | Team |
Sue Jefferies | Office Administrator | Team |
Alizée Wong | Team Lead (analytical Development) | Team |
Drew Hope | GMP Bio-Manufacturing & Compliance Consultant & EU QP | Team |
Mike Kilcooley | Bioprocess Scientist | Team |
Elliott Mainstone | Bioprocess Scientist | Team |
Hilary Geilinger | Financial Controller | Team |
Hanna Zielinska | Bioprocess Scientist | Team |
Gillian Lewis | GMP Bio-manufacturing Compliance Consultant, Qualified Person | Team |
Irvin Lee | Management Accountant | Team |
Charlotte Hughes | Project Manager | Team |
17 more people are available in the full profile.
Complete people profiles for eXmoor
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of eXmoor
3 dated milestones of eXmoor across 19 years, from founding to its latest funding, stage changes and deals.
- Founded eXmoor is founded.
- Funding First funding round of $16.7M.
- Funding Latest funding round, Series A, of $35.0M.
Competitors of eXmoor
eXmoor operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Orgenesis, Ori Biotech, MaSTherCell, Cognate Bioservices and Cell-Easy, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| orgenesis.com | 2008 | Germantown, United States | – | 167 | Cell and gene therapies for multiple disorders are developed. | |
| oribiotech.com | 2015 | London, United Kingdom | $281.12M | 52 | Software development services are provided for the biopharma sector. | |
| masthercell.com | 2011 | Charleroi, Belgium | $17.37M | 329 | Services for cell therapy development and manufacturing are provided. | |
| cognatebioservices.com | 2002 | Hanover, United States | – | 302 | Development and manufacturing services for cell-based therapies are provided. | |
| cell-easy.com | 2015 | Toulouse, France | – | – | Stem cell-based therapy services for research solutions are provided. | |
| genflowbio.com | 2020 | Charleroi, Belgium | – | 5 | A biotechnology company focused on anti-aging therapeutics development. | |
| exothera.world | 2020 | Brussels, Belgium | – | 131 | Clinical trial services to biopharma sector are provided by CDMO. | |
| splisense.com | 2016 | Jerusalem, Israel | $28.5M | – | Limited information available | |
| obiosh.com | 2013 | Shanghai, China | $87.09M | – | OBiO Technology is engaged in cell and gene therapy solutions. |
Detailed competitors of eXmoor
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of eXmoor
The website of eXmoor (exmoorpharma.com) receives about 1.9K visits a month.
- Monthly visits1.9K
▲ 19.4% vs previous month
Latest news on Exmoor
Complete news archive for eXmoor
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to eXmoor
10 companies that operate in the same segment as eXmoor (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 255.15 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about eXmoor
eXmoor was founded in 2004 and raised its 1st funding round 17 years after it was founded.
eXmoor is headquartered in Bristol, United Kingdom. It is registered at Bristol, England, United Kingdom.
eXmoor is a funded company, having raised a total of $51.75M across 2 funding rounds to date. The company's 1st funding round was a Series A of $16.75M, raised on Mar 2021.
eXmoor was founded in 2004 and is based in Bristol, United Kingdom. Cell and gene therapeutic services are delivered by the company to support the biopharmaceutical sector. Operations encompass development and manufacturing processes for advanced therapies. Focus is placed on regulatory compliance and scalable solutions for client needs in the United Kingdom and beyond. Expertise is applied to streamline therapeutic pipelines for pharmaceutical partners.
eXmoor's top competitors include Ori Biotech, MaSTherCell and OBiO Technology.
eXmoor offers Process Development, GMP Manufacture, Fill and Finish, and QP Release.
eXmoor has 2 investors. Key investors include MVM Partners, and Kineticos.
eXmoor operates through Exmoor Pharma Concepts Limited.